METHOD FOR DETERMINING INDIVIDUAL ACTIVITY OF 131-IODINE FOR RADIOIODINE THERAPY OF THYROTOXICOSIS AND PREDICTION OF TIME FOR ACHIEVING A SAFE LEVEL OF 131-IODINE ACTIVITY IN THE PATIENT'S BODY AFTER ADMINISTERING INDIVIDUAL 131-IODINE ACTIVITY Russian patent published in 2020 - IPC A61K51/00 A61P5/14 G16H20/10 G16H20/30 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to endocrinology, radiology, therapy, and can be used to determine individual activity of 131-iodine for radioiodine therapy of thyrotoxicosis, as well as predicting time to achieve a safe level of activity of 131-iodine in the patient's body after administering individual activity of 131-iodine. Method for determining individual activity of 131-iodine for radioiodine therapy of thyrotoxicosis involves determining the volume of (k) sections of thyroid tissue (Vk, [ml]), specific index of thyroid capture of 99mTc-pertechnetate (I, [%]), distribution of thyroid capture of 99mTc-pertechnetate over sections of thyroid tissue (Rk, [%]), as well as determination of maximum and integral thyroid capture of 131-iodine. Working solution is introduced orally in volume of 5 to 10 ml with activity content (A0) of 131-iodine from 5 to 10 MBq. Further, two dosimeters are placed on the patient's body and made with possibility of periodic recording of gamma-radiation power up to 2 mSv/h and autonomous operation up to 5 days: the first – at the level of the thyroid gland, the second – at the level of bladder. Gamma-power of is continuously recorded for 2–5 days, where j is the number of the dosimeter, p is the number of the registered value after a certain time interval from range of 2–15 minutes, with preservation of the registered data in the dosimeter memory. Thereafter, these values are converted into activity values of 131-iodine to obtain data sets A¹_p and A²_p with subsequent averaging of data for each hour of measurements to obtain arrays where i is number of hour after working solution introduction. Further, the therapeutic activity of the thyroid tissue is determined: if the specific index of the thyroide capture of 99mTc-pertechnetate is less than 0.5 %/ml by formula the specific index of the thyroid capture of 99mTc-pertechnetate is more than 0.5 %/ml by formula where is a dose accumulation factor, and if k=1, the individual therapeutic activity of 131-iodine is taken to be a minimum value of and if k>1, individual therapeutic activity of 131-iodine is determined by formula A_ind= where MU is maximum thyroide capture of 131-iodine, and UI is integral capture of 131-iodine, which are determined by formulas: or by formulas: where is an array of activity in the "Thyroid" chamber, obtained by processing the recorded data of the arrays using a four-chamber pharmacokinetics model of 131-iodine in the patient's body, taking into account the activity at each time t in the following chambers: "Body", "Thyroid", "Activity 131-iodine, derived from the body through the bladder", "The loss of 131-iodine activity as a result of radioactive decay". Time for achieving 131-iodine (T) safe level of activity in the patient is predicted after the individual activity of 131-iodine is introduced by formula: where A_n is normative safety of activity for population, λ_ef. is an effective output constant, determined by approximating an array of patient's activities in a patient's body by a single-exponential function where is the sum of activities and activity in the "Body" chamber.

EFFECT: method provides reducing a risk of recurrent thyrotoxicosis and more accurate prediction of the time of achieving a safe level of activity in the patient's body by determining individual activity of 131-iodine for radioiodine therapy taking into account individual pharmacokinetics.

6 cl, 7 dwg, 6 ex